Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

268.80
+1.520.57%
Post-market: 276.007.20+2.68%18:24 EST
Volume:403.02K
Turnover:108.50M
Market Cap:6.72B
PE:-20.80
High:274.35
Open:263.98
Low:263.84
Close:267.28
52wk High:278.44
52wk Low:26.70
Shares:25.01M
Float Shares:19.79M
Volume Ratio:0.30
T/O Rate:2.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.9227
EPS(LYR):-10.2095
ROE:-75.20%
ROA:-45.09%
PB:19.57
PE(LYR):-26.33

Loading ...

BUZZ-Praxis jumps on positive meeting with FDA for tremor drug, epilepsy trial success

Reuters
·
Dec 05

Wedbush Adjusts Praxis Precision Medicines PT to $83 From $77, Maintains Underperform Rating

MT Newswires Live
·
Dec 05

Praxis Precision Med Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 05

Praxis Precision Medicines Inc : Needham Raises Target Price to $304 From $250

THOMSON REUTERS
·
Dec 05

Praxis Precision Medicines, Inc. : Deutsche Bank Raises Target Price to $303 From $270

THOMSON REUTERS
·
Dec 05

Praxis Precision Medicines Shares Rise on Positive Preliminary Meeting with FDA for Essential Tremor Treatment

Dow Jones
·
Dec 05

Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What's Going On?

Benzinga_recent_news
·
Dec 05

Praxis Precision Medicines Announces Positive Results From Embold Study for Relutrigine in Scn2a and Scn8a Developmental and Epileptic Encephalopathies

THOMSON REUTERS
·
Dec 05

Praxis Precision Medicines Inc - FDA Confirms Meeting to Review Data and Discuss Next Steps

THOMSON REUTERS
·
Dec 05

Praxis Precision Medicines Reports Positive EMBOLD Study Results for Relutrigine in SCN2A and SCN8A Epileptic Encephalopathies

Reuters
·
Dec 05

Praxis Precision Medicines Inc - Expects Nda Submission Completion in Early 2026

THOMSON REUTERS
·
Dec 05

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

GlobeNewswire
·
Dec 05

Praxis Precision Medicines Grants Restricted Stock Units to New Employees

Reuters
·
Dec 04

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 04

Praxis Precision Med Price Target Maintained With a $250.00/Share by Needham

Dow Jones
·
Dec 01

Assessing the Valuation of Praxis Precision Medicines (PRAX) Following Short Report, Insider Sales, and Public Offering News

Simply Wall St.
·
Nov 26

Promising Potential of Ulixacaltamide in Essential Tremor Market Justifies Buy Rating

TIPRANKS
·
Nov 26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), AbSci (ABSI) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Nov 25

Praxis Precision Med Price Target Maintained With a $258.00/Share by HC Wainwright & Co.

Dow Jones
·
Nov 25

Praxis Precision Medicines (PRAX) Prepares for a Fireside Chat

TIPRANKS
·
Nov 21